Кардиоваскулярные эффекты противовоспалительных препаратов

1. <div><p>Кукес ВГ, Сычев ДА. Клиническая фармакология ненаркотических анальгетиков. Клин, фармакол. тер. 2002,5,73-78</p><p>Насонов Е.Л. Фармакотерапия боли: взгляд ревматолога. Консилиум, 2000,1,1-10.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине) Москва, "Анко", 2000, 143</p><p>Насонов Е.Л., Цветкова Е.С., Тов Н.Л. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер.архив, 1998,5,8-14.</p><p>Насонов ЕЛ. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы. Клин, фармакол. те- рап., 2000. 1,57-64.</p><p>Bombardier С. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am.J. Med. 2002.89, (suppl.), 3D-9D</p><p>Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA, 2000,284,1247-1255</p><p>Goldstein H, Silverstein FE, Agarwal NM et al. Reduced risk of upper gastrointestinal ulcers with celexocib: a novel COX-2 inhibitors. Am. J. Gastroenterol., 2000, 95, 16811690.</p><p>Schoenfeld P. Gastrointestinal safety profile of meloxicam: a metha-analysis and systematic review of randomizes controlled trials. Am. J. Med., 1999, 107 (6A), 48S-54S.</p><p>Wolfe F, Anderson J, Burke ТА et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J. Rheumatol., 2002, 29, 467-473.</p><p>Zeidler H, Kalwasser JP, Leonard JP. et al. Prescribtion and tolerability of meloxicam in day-to-day practice. Postmarketing observational cohort study of 13307 patients in Germany. J. Clin. Rheumatol., 2002, 8, 1-11.</p><p>National Institute of Clinical Exellence. Guidlance on the use of cyclo-oxygenase (COX) 2 selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Apprasial Guidlance - No. 27. London Goverment publication. 2001.</p><p>Feuba DA. Gastrointestinal safety and tolerability of non- selective nonsteroidal anti-inflammatory agents and cycloxygenase-2 selective inhibitors. Clevelend Clinic J. Med .,2002, 69, suppl 10, S1-31-SI-39.</p><p>Crofford U, Lipsky PE, Brooks P. et al. Basic biology and clinical application of specific cycloxygenase-2 inhibitors. Arthr. Rheum., 2000, 43, 3157-33160.</p><p>Fitzgerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. New Engl. J. Med., 2001, 345, 433442.</p><p>Mukhetjee D, Nissen SE, Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959</p><p>McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitors of COX-2. PNAS, 1999, 96. 272-277.</p><p>Cheng Y, Austin SC, Rocca B. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science, 2002, 296, 539-541.</p><p>Hennan JK, Huang J. Barrett TD. et al. Effects of selective cyclooxygenase-2 inhibition on vascular response and thrombosis in canine arteries. Circulation, 2001, 104, 820825.</p><p>Shinmura K, Tang XL, Wang Y et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase ischemic preconditioning in conscious rabbits. Proc. Nat. Acad. Sci.USA ,2000, 97,10197-10202.</p><p>Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal. Arthr. Rheum., 2003, 48, 12-20.</p><p>Marcus AJ, Broekman MJ, Pinsky GJ. COX inhibition and thromboregulation. New Engl. J. Med., 2002, 347, 10251026.</p><p>Bombardier C, Lane L. Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl. J. Med., 2000, 343, 1520-1528.</p><p>Crofford LJ, Oates JC, McCune WI et al. Thrombosis in patients with connective tissue disease treated with specific cycloxygenase-2 inhibitors: a report of four cases. Arthr. Rheum. 2000, 43, 1891-1896.</p><p>White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib. a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J. Cardiol., 2002, 89, 425-430.</p><p>Konstam МА. Weir AR. Current persective on the cardiovascular effects of coxibs. Clev.Clin. J. Med,, 2002, (suppl 1), SI-47-S1-52.</p><p>Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective eyclooxygenase-2 inhibitors. Arthr. Rheum., (Arth. Care&amp;Res.). 2002, 47,349-355. 2S. White WB, Faich G, Borer JS, Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase-</p><p>inhibitor - celecoxib. ACR 66th Annual Scientific Meeting, New Orleans. 2002. 485.</p><p>Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory druds (ibuprofen, diclofenac and nabumeton). Am. Cardiol., 2002, 89, 204209.</p><p>Singh GS, Gamier P. Hwang E. et al. Meloxicam does not increase the risk of cardiovascular adverse events compared to other NSAIDs: results from the IMPROVE trial, a multi-center, randomized parallel-group, open label study of 1309 patients in a managed case setting. EULAR Ann. Cong, of Rheumatol. Stockholm, Sweden, THU0259 (abst).</p><p>Warner TD, Mitchell JA. Vane JR Cyclooxygenase-2 inhibitors and cardiovascular events. Lancet ,2002, 360, 1700-1701.</p><p>Lander SA, Wallace DJ, Weisman MH Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus, 2002, 11, 340-347</p><p>KnijtT-Dutmer EAJ, Kalsbeek-Batenburg EM, Kocrts J, van Laar MAFJ. Platelet function is inhibited by non-selec- tive non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatol., 2002, 41, 458-461.</p><p>Van Hecken A., Schwarts JL. Depre М., et al. Comparative inhibitory activity of rofecoxib, meloxicam. diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharm. 2000, 40, 1109-1120</p><p>Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. 2002, 162, 1111-1115.</p><p>Solomon DH, Glynn RJ, Lcvone R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med., 2002, 162, 1099-1104</p><p>Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med., 2002. 162, 1105-1110</p><p>Hudson M, Baron M. Rahme E, Pilot L. Anti-inflammatory drugs with a decrease risk of recurrent acute myocardial infarction in patients on aspirin. ACR 66th Annual Scientific Meeting, New Orleans, 2002; 1663 (abst).</p><p>Ко D., Wang Y, Berger AK. et al. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J., 2002. 143. 475-481.</p><p>Garcia Rodriguez LA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemilogic data. Clin. Exp. Rheumatol.,2001,</p><p>(suppl. 25). S41-S45.</p><p>Ray WA, Stein CM, Hall K. et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet, 2002, 359, 118-123.</p><p>Bak S, Andersen M, Tsiropoulos I. et al. Risk of stroke associated with nonsteeroidal anti-inflammatory drugs. Stroke, 2003.34,379-395</p><p>Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. New Engl. J. Med., 2001. 345. 1809-1817.</p><p>Van Solingen R.M., Rosenstein E.D., Mihailescu G., et al. Comparison of the effects of ketoprofen on platelet fbnction in the presence and absence of aspirin. Am. J. Med., 2001, 111, 285-289</p><p>Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced intereference of platelet cyclooxygenase-1 inactivation by aspirin. PNAS, 2001, 98, 14583-14588.</p><p>Greenberg H, Gottesdiener K, Huntington M, et al, A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J. Clin. Pharm., 2000, 40, 1509-1515.</p><p>Ross R. Atherosclerosis an inflammatory disease. New Engl. J. Med., 1999, 340, 115-126.</p><p>Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002, 105, 1135-1143</p><p>Насонов Е.Л. Атеротромбоз при ревматических заболеваниях: анализ патогенеза Тер. архив, 1998, 9,92-95.</p><p>Baker CS, Hall RJ. Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages. Atheroscler. Thromb. Vase. Biol., 1999, 19, 646-655.</p><p>Schonbeck U. Sukhova GK. Graber P. et al. Augmented expression of cyclooxigenase-2 in human atherosclerotic lesions. Am. J. Pathol., 1999, 155, 1281-1291.</p><p>Burleigh ME. Babaev VR, Oates JA. et al. Cyclooxyge- nase-2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation, 2002, 105, 1816-1823.</p><p>Cippilone F, Prontera C., Pini B. et al. Overexpression of functionally coupled cyclooxygenase E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2- dependent plaque instability. Circulation ,2001, 104, 921930.</p><p>Salto T, Rodger IW, Ни E. et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biophys. Res. Commun., 2000, 273, 772-775,</p><p>Chenevard R., Hurlimann D., Bechir M. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation ,2003, 107.</p><p>Heindt H, Becker BF. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischeinic cardiac dysfunction, independent of COX function. Naunyn-Schmiedebcrg's Arch. Pharmacol., 2001, 363,233-240.</p><p>Belton O, Byrne D. Kearney D. et al. Cyclooxygenase-1 and - 2 dependent prostacyclin formation in patients with atherosclerosis. Circulation , 2000, 102, 840-845.</p><p>Altman R. Luciardi HL, Muntaner J., et al. Efficacy of assessment of meloxicam. A preferential COX-2 inhibitor in acute coronary syndromes without ST-segment elevation, the NUT-2 pilot study. Circulation. 2002, 106. 191-195.</p></div><br />